The efficacy and tolerability of paroxetine, a selective serotonin reuptake inhibitor, were evaluated in a 12-week, single-blind, randomized study. Forty outpatients with fibromyalgia syndrome (FMS) were allocated to receive paroxetine 20 mg once daily for 3 months (group A; n = 20) or placebo once daily for 3 months (group B; n = 20), The investigator's overall assessment of paroxetine's efficacy was much improved or improved in 68% of group A patients, slightly improved in 24%, and no change in 8%, Group A patients' overall assessment of paroxetine's efficacy was much improved or improved in 40%, slightly improved in 48%, and no change in 12%, The investigator's and group 13 patients' overall assessments of the placebo's efficacy were no change in 96% and 82% and slightly improved in 4% and 18%, respectively. The investigator's overall assessment of tolerability was very good or good in 82% of group A patients and very good or good in 98% of group B patients. The patients' overall assessment of tolerability was very good or good in 70% in group A and in 18% in group B. Based on the findings, paroxetine appeared to be effective and well tolerated in our group of patients with FMS.
Giordano, N., Geraci, S., Santacroce, C., Mattii, G., Gennari, C. (1999). Efficacy and tolerability of paroxetine in patients with fibromyalgia syndrome: a single-blind study. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 60(12), 696-702 [10.1016/S0011-393X(99)90008-5].
Efficacy and tolerability of paroxetine in patients with fibromyalgia syndrome: a single-blind study
Giordano, N.;
1999-01-01
Abstract
The efficacy and tolerability of paroxetine, a selective serotonin reuptake inhibitor, were evaluated in a 12-week, single-blind, randomized study. Forty outpatients with fibromyalgia syndrome (FMS) were allocated to receive paroxetine 20 mg once daily for 3 months (group A; n = 20) or placebo once daily for 3 months (group B; n = 20), The investigator's overall assessment of paroxetine's efficacy was much improved or improved in 68% of group A patients, slightly improved in 24%, and no change in 8%, Group A patients' overall assessment of paroxetine's efficacy was much improved or improved in 40%, slightly improved in 48%, and no change in 12%, The investigator's and group 13 patients' overall assessments of the placebo's efficacy were no change in 96% and 82% and slightly improved in 4% and 18%, respectively. The investigator's overall assessment of tolerability was very good or good in 82% of group A patients and very good or good in 98% of group B patients. The patients' overall assessment of tolerability was very good or good in 70% in group A and in 18% in group B. Based on the findings, paroxetine appeared to be effective and well tolerated in our group of patients with FMS.File | Dimensione | Formato | |
---|---|---|---|
efficacy and tolerab.pdf
non disponibili
Tipologia:
Post-print
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
431.9 kB
Formato
Adobe PDF
|
431.9 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/42850
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo